Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib

References

• Azim HA Jr., Agbor-Tarh D, Bradbury I, et al. (2013). Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial. J Clin Oncol 31:4504–4511
   PubMed Web of Science ®Google Scholar
• Barbara JE, Kazmi F, Parkinson A, Buckley DB. (2013). Metabolism-dependent inhibition of CYP3A4 by lapatinib: Evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate. Drug Metab Dispos 41:1012–1022
   PubMed Web of Science ®Google Scholar
• Beaune P, Dansette PM, Mansuy D, et al. (1987). Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 84:551–555
   PubMed Web of Science ®Google Scholar
• Castellino S, O'Mara M, Koch K, et al. (2012). Human metabolism of lapatinib, a dual kinase inhibitor: Implications for hepatotoxicity. Drug Metab Dispos 40:139–150
   PubMed Web of Science ®Google Scholar
• Chan EC, New LS, Chua TB, et al. (2012). Interaction of lapatinib with cytochrome P450 3A5. Drug metabolism and disposition: The biological fate of chemicals 40:1414–1422
   Google Scholar
• Chan JCY, Choo DYM, Chan ECY. (2014). Impact of CYP3A5 genetic polymorphism on mechanism-based inactivation by lapatinib. In: 19th North American ISSX and 29th JSSX joint meeting, pp Abstract P287, San Francisco, United States
   Google Scholar
• Dabrowski MJ, Schrag ML, Wienkers LC, Atkins WM. (2002). Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: Evidence for a multiple substrate binding site. J Am Chem Soc 124:11866–11867
   PubMed Web of Science ®Google Scholar
• de Jonge MJ, Hamberg P, Verweij J, et al. (2013). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 31:751–759
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, Backman JT. (2012). Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165:2787–2798
   PubMed Web of Science ®Google Scholar
• Frampton JE. (2009). Lapatinib: A review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 69:2125–2148
   PubMed Web of Science ®Google Scholar
• Ge GB, Ning J, Hu LH, et al. (2013). A highly selective probe for human cytochrome P450 3A4: Isoform selectivity, kinetic characterization and its applications. Chem Commun (Camb) 49:9779–9781
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, et al. (2008). Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999–3005
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: Regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 39:1–17
   PubMed Web of Science ®Google Scholar
• Hardy KD, Wahlin M, and Rettie AE (2014a) Role of CYP3A5 in the Metabolic Activation of Lapatinib, in: 53rd Annual Meeting of the Society of Toxicology pp S143, Oxford University Press, Pheonix, Arizona, USA
   Google Scholar
• Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, and Nelson SD (2014b) Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells. Drug metabolism and disposition: the biological fate of chemicals 42:162–171
   Google Scholar
• Harrelson JP, Stamper BD, Chapman JD, et al. (2012). Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen. Drug Metab Dispos 40:1460–1465
   PubMed Web of Science ®Google Scholar
• Homberg JC, Andre C, Abuaf N. (1984). A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 55:561–570
   PubMed Web of Science ®Google Scholar
• Jelovac D, Wolff AC. (2012). The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 13:230–239
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–1294
   PubMed Web of Science ®Google Scholar
• Li X, Jeso V, Heyward S, et al. (2014). Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity. Drug Metab Dispos 42:334–342
   PubMed Web of Science ®Google Scholar
• Lin HL, Kenaan C, Hollenberg PF. (2012). Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos 40:998–1006
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia MP, Dansette PM, Mansuy D. (1994). Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33:166–175
   PubMed Web of Science ®Google Scholar
• Marks GS, McCluskey SA, Mackie JE, et al. (1988). Disruption of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P-450. FASEB J 2:2774–2783
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Horie T. (2007). Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit Rev Toxicol 37:389–412
   PubMed Web of Science ®Google Scholar
• Midgley RS, Kerr DJ, Flaherty KT, et al. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 18:2025–2029
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–255
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR. (2005). Cytochrome P450: Structure, mechanism, and biochemistry. New York: Kluwer Academic/Plenum Publishers
   Google Scholar
• Rezai K, Urien S, Isambert N, et al. (2011). Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol 68:1529–1536
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51–66
   PubMed Web of Science ®Google Scholar
• Rock DWLC. (2010). Characterization of cytochrome P450 mechanism-based inhibition. In: Gad SC, ed. Pharmaceutical sciences encyclopedia: Drug discovery, development, and manufacturing. New York: John Wiley & Sons, 56
   Google Scholar
• Smith DA, Koch KM, Arya N, et al. (2009). Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67:421–426
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Budde LR, Briley LP, et al. (2011). HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29:667–673
   PubMed Web of Science ®Google Scholar
• Takakusa H, Wahlin MD, Zhao C, et al. (2011). Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos 39:1022–1030
   PubMed Web of Science ®Google Scholar
• Teng WC, Oh JW, New LS, et al. (2010). Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78:693–703
   PubMed Web of Science ®Google Scholar
• Teo YL, Saetaew M, Chanthawong S, et al. (2012). Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidence. Breast Cancer Res Treat 133:703–711
   PubMed Web of Science ®Google Scholar
• Thunell S, Pomp E, Brun A. (2007). Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 64:668–679
   PubMed Web of Science ®Google Scholar
• Uetrecht J. (2007). Idiosyncratic drug reactions: Current understanding. Ann Rev Pharmacol Toxicol 47:513–539
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Hyland R, et al. (2012). Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686–1697
   PubMed Web of Science ®Google Scholar